An activation-specific monoclonal antibody (MoAb) termed “Canine Activated Platelet 1” (CAP1) has been developed and partially characterized. Flow cytometric studies of isolated canine platelets, using adenosine diphosphate (ADP) and platelet activating factor (PAF) as agonists, demonstrated that CAP1 binding site number was proportional to agonist strength and agonist concentration. MoAb CAP1 binding was diminished by ethylenediamine-tetraacetic acid, suggesting that the antigen was either stabilized by calcium or antigen binding to the platelet surface was mediated by calcium. ADP-activated gel-filtered platelets also demonstrated reduced binding of MoAb CAP1 even in the presence of 1 mM CaCl2. Binding of MoAb CAP1 could be partially restored by activating gel-filtered platelets with PAF, suggesting that the antigen was either present within platelet granule membranes or was exposed after binding of released protein(s) with a platelet receptor. A monoclonal antibody to human platelet glycoprotein IIIa (GPIIIa), which cross-reacts with canine platelet GPIIIa regardless of platelet activation status, did not inhibit binding of MoAb CAP1. MoAb CAP1 bound to isolated canine fibrinogen captured on polystyrene microtiter plates in the absence of platelet proteins. Immunoblots indicated that MoAb CAP1 recognizes nonreduced fibrinogen as well as a plasmin digest of isolated canine fibrinogen. Results of the present studies suggest that MoAb CAPI recognizes a receptor-induced binding site on canine fibrinogen.
AbramsCSEllisonNBudzynskiAZShattilSJ:
Direct detection of activated platelets and platelet-derived microparticles in humans.
Blood75
(1):
128–138,
1990
2.
AsadaYHayashiTSumiyoshiA:
Vascular injuries induced by materials released from platelet-rich thrombus in vivo.
Atherosclerosis70:
1–6,
1988
3.
BornG:
Aggregation of blood platelets by adenosine diphosphate and its reversal.
Nature194:
927–929,
1962
4.
BoudreauxMKDillonARSpanoJS:
Enhanced platelet reactivity in heartworm-infected dogs.
Am J Vet Res50
(9):
1544–1547,
1989
5.
BradfordMM:
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.
Anal Biochem72:
248–254,
1976
6.
BrassLFShattilSJKunickiTJBennettJS:
Effect of calcium on the stability of the platelet membrane glycoprotein IIb-IIIa complex.
J Biol Chem260
(13):
7875–7881,
1985
7.
CadroyYHansonSRKellyABMarzecUMEvattBLKunickiTJMontgomeryRRHarkerLA:
Relative antithrombotic effects of monoclonal antibodies targeting different platelet glycoprotein-adhesive molecule interactions in nonhuman primates.
Blood83
(11):
3218–3224,
1994
8.
CalveteJJ:
Clues for understanding the structure and function of a prototypic human integrin: the platelet glycoprotein IIb/IIIa complex.
Thromb Haemostasis72
(1):
1–15,
1994
9.
DoolittleRFSchubertDSchwartzSA:
Amino acid sequence studies on artiodactyl ∗∗∗fibrinopeptides. I. Dromedary camel, mule deer, and cape buffalo.
Arch Biochem Biophys118:
456–467,
1967
10.
DoreMHawkinsHKEntmanMLSmithCW:
Production of a monoclonal antibody against canine GMP-140 (P-selectin) and studies of its vascular distribution in canine tissues.
Vet Pathol30:
213–222,
1993
11.
DoreMKorthuisRJGrangerDNEntmanMLSmithCW:
P-selection mediates spontaneous leukocyte rolling in vivo.
Blood82
(4):
1308–1316,
1993
12.
DunbarBSSkinnerSM:
Preparation of monoclonal antibodies.
In:
Methods in Enzymology,
ed. DeutscherMP,
vol. 182,
pp. 670–679.
Academic Press, Inc,
San Diego, CA,
1990
13.
FrelingerALIIICohenIPlowEFSmithMARobertsJLamSC-TGinsbergMH:
Selective inhibition of integrin function by antibodies specific for ligand-occupied receptor conformers.
J Biol Chem265
(11):
6346–6352,
1990
14.
GinsbergMHFreiingerALLamSCTForsythJMcMillanRPlowEFShattilSJ:
Analysis of platelet aggregation disorders based on flow cytometric analysis of membrane glycoprotein IIb-IIIa with conformation-specific monoclonal antibodies.
Blood76
(10):
2017–2023,
1990
15.
HoffmanMMonroeDMRobertsHR:
Coagulation factor IXa binding to activated platelets and platelet-derived microparticles: a flow cytometric study.
Thromb Haemostasis68
(1):
74–78,
1992
16.
JanesSLGoodallAH:
Flow cytometric detection of circulating activated platelets and platelet hyper-responsiveness in pre-eclampsia and pregnancy.
Clin Sci86:
731–739,
1994
LanzaFBeretzAStierleAHanauDKubinaMCazenaveJP:
Epinephrine potentiates human platelet activation but is not an aggregating agent.
Am J Physiol255
(6):
H1276–H1288,
1988
19.
LindahlTLFestinRLarssonA:
Studies of fibrinogen binding to platelets by flow cytometry: an improved method for studies of platelet activation.
Thromb Haemostasis68
(2):
221–225,
1992
20.
McEverRPMartinMN:
A monoclonal antibody to a membrane glycoprotein binds only to activated platelets.
J Biol Chem259:
9799–9804,
1984
21.
MeyersKWardropKJ:
Platelets and coagulation.
In:
Advances in Veterinary Science and Comparative Medicine,
ed. CotterS,
vol. 36,
pp. 87–150.
Academic Press, Inc,
San Diego, CA,
1991
22.
NesheimMEFurmaniak-KazmierczakEHeninCCoteG:
On the existence of platelet receptors for factor V(a) and factor VIII(a).
Thromb Haemostasis70
(1):
80–86,
1993
23.
PlowEFD'SouzaSGinsbergMH:
Consequences of the interaction of platelet membrane glycoprotein GPIIb-IIIa (αIIbβ3) and its ligands.
J Lab Clin Med120
(2):
198–204,
1992
24.
RodgersGM:
Hemostatic properties of normal and perturbed vascular cells.
Fed Am Soc Exp Biol J2:
116–123,
1988
25.
ScharfRETomerAMarzecUMTeirsteinPSRuggeriZMHarkerLA:
Activation of platelets in blood perfusing angioplasty-damaged coronary arteries. Flow cytometric detection.
Arterioscler Thromb12:
1475–1487,
1992
26.
SharrowSO:
Overview of flow cytometry.
In:
Current Protocols in Immunology,
ed. ColiganJEKruisbeekAMMarguliesDHShevachEMStroberW,
pp. 5.1.1–5.1.8.
John Wiley & Sons,
New York, NY,
1991
27.
SharrowSO:
Analysis of flow cytometry data.
In:
Current Protocols in Immunology,
ed. ColiganJEKruisbeekAMMarguliesDHShevachEMStroberW,
pp. 5.2.1–5.2.10.
John Wiley & Sons,
New York, NY,
1991
28.
ShattilSJCunninghamMHoxieJA:
Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry.
Blood70
(1):
307–315,
1987
29.
ShattilSJHoxieJACunninghamMBrassLF:
Changes in the platelet membrane glycoprotein IIb-IIIa complex during platelet activation.
J Biol Chem260
(20):
11107–11114,
1985
30.
SilversteinRLFebbraioM:
Identification of lysosome-associated membrane protein-2 as an activation-dependent platelet surface glycoprotein.
Blood80
(6):
1470–1475,
1992
31.
StelHVSakariassenKSde GrootPGvan MourikJASixmaJJ:
Von Willebrand factor in the vessel wall mediates platelet adherence.
Blood65:
85–90,
1985
32.
TomiyamaYBrojerERuggeriZMShattilSJSmiltneckJGorskiJKumarAKieber-EmmonsTKunickiTJ:
A molecular model of RGD ligands.
Antibody D gene segments that direct specificity for the integrin αIIbβ3 J Biol Chem267
(25):
18085–18092,
1992
33.
ZamarronCGinsbergMHPlowEF:
Monoclonal antibodies specific for a conformationally altered state of fibrinogen.
Thromb Haemostasis64
(1):
41–46,
1990
34.
ZamarronCGinsbergMHPlowEF:
A receptor induced-binding site in fibrinogen elicited by its interaction with platelet membrane glycoprotein IIb-IIIa.
J Biol Chem266:
16193–16199,
1991
